Clinical Trial Detail

NCT ID NCT03123393
Title TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

diffuse large B-cell lymphoma

Therapies

Mivavotinib

Age Groups: adult senior

No variant requirements are available.